Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Launched by SUN PHARMACEUTICAL INDUSTRIES, INC. · Aug 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called deuruxolitinib to see if it is safe and effective for treating severe alopecia areata in teenagers. Alopecia areata is a condition that causes hair loss, and this study focuses on adolescents aged 12 to under 18 years who have lost at least half of the hair on their scalp. The goal is to find out if deuruxolitinib can help these young people regrow their hair and improve their condition.

To join the study, participants need to have had alopecia areata for at least six months but no more than ten years, and their hair loss must cover 50% or more of their scalp. Teens who have other scalp problems or are using certain medications that might affect hair growth cannot take part. Female participants who are pregnant, nursing, or planning to become pregnant during the study are also not eligible. Those who join will be asked to follow the study’s schedule and requirements, which includes regular visits to check their progress and safety. This trial is currently recruiting participants, and it welcomes teens of all genders who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years.
• • Between 12 to \<18 years of age
• • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50.
• • Willing to comply with the study visits and requirements of the study protocol
• Exclusion Criteria:
• • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis at Screening and/or Baseline
• • Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response.
• • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
• • Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.